MN-DIGI-INTERNATIONAL
Digi International (NASDAQ: DGII, www.digi.com ), a leading global provider of Internet of Things (IoT) connectivity products and services, today unveiled Digi IX30, an industrial-hardened cellular router solution for harsh environments. Digi IX30 provides edge intelligence in a ruggedized, industry-leading design for the highest levels of reliability and flexibility. Coupled with Digi Remote Manager ® , Digi IX30 is an all-in-one solution for applications including distribution and automation, as well as remote machine and sensor monitoring in industries such as oil and gas production, water utilities, smart cities, and outdoor signage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005021/en/
Digi IX30 is powered by Digi Remote Manager (Digi RM) and the Digi Accelerated Linux operating system (DAL OS). Digi RM is the command center of an intelligent network, enabling companies to efficiently configure, deploy, monitor, and manage tens of thousands of mission-critical devices and assets from a single desktop, tablet or smartphone. DAL OS, along with Digi RM, enables programmability for edge intelligence applications, interoperability for legacy serial devices/protocols, and MQTT Sparkplug B. These capabilities deliver critical connectivity between devices and sensors in the Industry 4.0 ecosystem, allowing users to experience high levels of security, control, and performance.
Ready for Public or Private Cellular Networks in ONE Solution
Digi IX30 delivers fast performance for public, private, and hybrid network deployments that support both licensed spectrum and CBRS Band 48 to enable migration between multiple networks in a single SKU. A future variant of Digi IX30 will include Anterix Band 8 along with Anterix Active certification to offer public and Anterix private cellular network support.
Battle Tested for Harsh Environments
Digi has designed its entire industrial (IX) product family to meet high-performance requirements in harsh environments with wide temperature ranges. Its Class 1, Division 2 (C1D2) and ATEX certifications makes it suitable for environments where potentially explosive gases, vapors, dust, or fibers may be present, and its DIN rail mounting design enables easy installation in field containers and cabinets.
Highest Density of I/O Options, Edge Intelligence and Complete Features for Global Deployments
Digi IX30 has the highest number of analog and digital I/O and serial ports along with rich protocol support and offers versatile integration options to manage a large of number of legacy systems from a single piece of equipment.
Digi IX30 was designed with dual Ethernet ports and GNSS, as well as support for remote sensors with four analog and four digital inputs and outputs. Leveraging its new Python programming implementation that provides interoperability with legacy serial devices/protocols, the Digi IX30 solution brings greater reliability, simplicity, and security to edge computing.
For customers who deploy and manage systems globally, Digi’s IX line provides a single SKU for high-volume global deployment, which simplifies inventory and reduces the costs of global distribution, deployment, and management.
“Digi IX30 – the newest member of our next-generation IX family of devices – builds on our widely successful legacy of industrial cellular routers,” said Sayeed Quazi, Sr. Principal Product Manager at Digi. “The ruggedized IX30, with additional compute for edge applications and additional analog and digital I/O, reduces the points of failure by eliminating the need for additional equipment. Its faster performance and LTE speeds deliver greater value through a complete, cost-effective IoT solution and significantly reduces OPEX in the most challenging deployment.”
The Digi IX30 industrial router is available immediately through global distributors.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005021/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom